237 related articles for article (PubMed ID: 28445400)
1. Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis.
Chiramel J; Backen AC; Pihlak R; Lamarca A; Frizziero M; Tariq NU; Hubner RA; Valle JW; Amir E; McNamara MG
Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28445400
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer.
Chan DLH; Segelov E; Wong RS; Smith A; Herbertson RA; Li BT; Tebbutt N; Price T; Pavlakis N
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD007047. PubMed ID: 28654140
[TBL] [Abstract][Full Text] [Related]
3. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
4. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
5. Anti-epidermal growth factor receptor therapy for glioblastoma in adults.
Lee A; Arasaratnam M; Chan DLH; Khasraw M; Howell VM; Wheeler H
Cochrane Database Syst Rev; 2020 May; 5(5):CD013238. PubMed ID: 32395825
[TBL] [Abstract][Full Text] [Related]
6. EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104.
Boeck S; Jung A; Laubender RP; Neumann J; Egg R; Goritschan C; Vehling-Kaiser U; Winkelmann C; Fischer von Weikersthal L; Clemens MR; Gauler TC; Märten A; Klein S; Kojouharoff G; Barner M; Geissler M; Greten TF; Mansmann U; Kirchner T; Heinemann V
Br J Cancer; 2013 Feb; 108(2):469-76. PubMed ID: 23169292
[TBL] [Abstract][Full Text] [Related]
7. Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial.
Wang JP; Wu CY; Yeh YC; Shyr YM; Wu YY; Kuo CY; Hung YP; Chen MH; Lee WP; Luo JC; Chao Y; Li CP
Oncotarget; 2015 Jul; 6(20):18162-73. PubMed ID: 26046796
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
Qi YT; Hou Y; Qi LC
Technol Cancer Res Treat; 2020; 19():1533033820940426. PubMed ID: 32723164
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety profile of combining agents against epidermal growth factor receptor or vascular endothelium growth factor receptor with gemcitabine-based chemotherapy in patients with advanced pancreatic cancer: a meta-analysis.
Tian W; Ding W; Kim S; Xu X; Pan M; Chen S
Pancreatology; 2013; 13(4):415-22. PubMed ID: 23890141
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the efficacy and safety of EFGR tyrosine kinase inhibitor monotherapy with standard second-line chemotherapy in previously treated advanced non-small-cell lung cancer: a systematic review and meta-analysis.
Qi WX; Shen Z; Lin F; Sun YJ; Min DL; Tang LN; He AN; Yao Y
Asian Pac J Cancer Prev; 2012; 13(10):5177-82. PubMed ID: 23244131
[TBL] [Abstract][Full Text] [Related]
11. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
[TBL] [Abstract][Full Text] [Related]
12. A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate?
Ciliberto D; Staropoli N; Caglioti F; Gualtieri S; Fiorillo L; Chiellino S; De Angelis AM; Mendicino F; Botta C; Caraglia M; Tassone P; Tagliaferri P
Cancer Biol Ther; 2015; 16(8):1148-59. PubMed ID: 26061272
[TBL] [Abstract][Full Text] [Related]
13. KRAS mutation as a prognostic factor and predictive factor in advanced/metastatic non-small cell lung cancer: A systematic literature review and meta-analysis.
Goulding RE; Chenoweth M; Carter GC; Boye ME; Sheffield KM; John WJ; Leusch MS; Muehlenbein CE; Li L; Jen MH; Rojubally A; Jansen J; Druyts E
Cancer Treat Res Commun; 2020; 24():100200. PubMed ID: 32750661
[TBL] [Abstract][Full Text] [Related]
14. No survival benefit from adding cetuximab or panitumumab to oxaliplatin-based chemotherapy in the first-line treatment of metastatic colorectal cancer in KRAS wild type patients: a meta-analysis.
Zhou SW; Huang YY; Wei Y; Jiang ZM; Zhang YD; Yang Q; Xie DR
PLoS One; 2012; 7(11):e50925. PubMed ID: 23226426
[TBL] [Abstract][Full Text] [Related]
15. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
[TBL] [Abstract][Full Text] [Related]
16. Exceptional response to Erlotinib monotherapy in EGFR Exon 19-deleted, KRAS wild-type, Chemo-refractory advanced pancreatic adenocarcinoma.
Park R; Al-Jumayli M; Miller K; Saeed A; Saeed A
Cancer Treat Res Commun; 2021; 27():100342. PubMed ID: 33611092
[TBL] [Abstract][Full Text] [Related]
17. Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF.
Blasco MT; Navas C; Martín-Serrano G; Graña-Castro O; Lechuga CG; Martín-Díaz L; Djurec M; Li J; Morales-Cacho L; Esteban-Burgos L; Perales-Patón J; Bousquet-Mur E; Castellano E; Jacob HKC; Cabras L; Musteanu M; Drosten M; Ortega S; Mulero F; Sainz B; Dusetti N; Iovanna J; Sánchez-Bueno F; Hidalgo M; Khiabanian H; Rabadán R; Al-Shahrour F; Guerra C; Barbacid M
Cancer Cell; 2019 Apr; 35(4):573-587.e6. PubMed ID: 30975481
[TBL] [Abstract][Full Text] [Related]
18. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.
Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X
Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682
[TBL] [Abstract][Full Text] [Related]
19. Combination of EGFR-TKIs and chemotherapy as first-line therapy for advanced NSCLC: a meta-analysis.
OuYang PY; Su Z; Mao YP; Deng W; Xie FY
PLoS One; 2013; 8(11):e79000. PubMed ID: 24236082
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
Qin K; Hou H; Liang Y; Zhang X
BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
